<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1286">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567813</url>
  </required_header>
  <id_info>
    <org_study_id>V501-070</org_study_id>
    <secondary_id>EP08014.070</secondary_id>
    <nct_id>NCT01567813</nct_id>
  </id_info>
  <brief_title>Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)</brief_title>
  <official_title>Post-Licensure Observational Study of the Safety of GARDASIL™ in Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-licensure safety observation cohort study to describe the general safety of
      GARDASIL™ (a quadrivalent human papillomavirus vaccine) in males.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Incidence of health outcomes resulting in emergency room visits or hospitalizations in 60-day risk periods after each dose of GARDASIL™ compared to post-vaccination self-comparison periods</measure>
    <time_frame>Within 60 days after each dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of health outcomes resulting in emergency room visits or hospitalizations in the 60-day risk period following the first dose of GARDASIL™ compared to post-vaccination self-comparison periods</measure>
    <time_frame>Within 60 days after the first dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of syncope, convulsive syncope, epilepsy, convulsions, head trauma, and allergic reactions on the day of vaccination</measure>
    <time_frame>Day of vaccination for each dose received (1 day for each dose, up to 3 total days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pre-specified new-onset conditions identified from the hospital, outpatient, and emergency room setting for 6 months after each dose of GARDASIL™ compared to the incidence of these conditions in an un-vaccinated population of males</measure>
    <time_frame>Within 6 months after each dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">44000</enrollment>
  <condition>Human Papilloma Virus Infection</condition>
  <arm_group>
    <arm_group_label>Regimen Initiators</arm_group_label>
    <description>Any male health plan member who receives at least one dose of GARDASIL™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen Completers</arm_group_label>
    <description>Regimen Initiators who complete the 3-dose vaccination regimen within 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune cohort</arm_group_label>
    <description>Regimen Initiators who were members of the health plan during the 12-month period prior to their first dose of GARDASIL™</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Males who are members of a large geographically diverse US health plan.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male vaccinated with at least one dose of GARDASIL™ after the October 2009 FDA date
             of first licensure of GARDASIL™ for males

        Exclusion criteria all cohorts:

          -  Female

          -  Male vaccinated prior to the October 2009 FDA date of first licensure of GARDASIL™
             for males

          -  Male who received all doses of GARDASIL™ outside of the health plan

        Exclusion criteria, Regimen Completers cohort:

          -  Male &lt; 9 and &gt; 26 years of age at first dose

          -  Male not part of health plan at each dose

          -  3-dose vaccination regimen given over a period &gt; 12 months

          -  Less than 28-day interval between first and second dose

          -  Less than 12 weeks between the second and third dose

          -  Less than 24 weeks between first and third dose

        Exclusion criteria, Autoimmune cohort:

        - Male with less than 12 months of health plan membership prior to first dose of GARDASIL™
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 30, 2015</lastchanged_date>
  <firstreceived_date>March 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Warts</keyword>
  <keyword>Papillomavirus infections</keyword>
  <keyword>DNA virus infections</keyword>
  <keyword>Virus diseases</keyword>
  <keyword>Skin diseases, viral</keyword>
  <keyword>Tumor virus infections</keyword>
  <keyword>Skin diseases, infectious</keyword>
  <keyword>Skin diseases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
